Abstract
Neutralizing antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) exhibit distinct patterns of potency, breadth, and resilience, yet the molecular mechanisms underlying these differences remain incompletely understood.
Funding Information
  • National Institutes of Health (1R01AI181600-01)
  • National Institutes of Health (5R01AI181600-02)
  • National Institutes of Health (Subaward 6069-SC24-11)